Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation

Cancer Research

Volumn 55, Issue 4, 1995, Pages 810-816

  Chen, Tian Ling ^a   Passos Coelho, Jose L ^a   Noe, Dennis A ^a   Kennedy, M John ^a   Black, Kraig C ^a   Colvin, O Michael ^a   Grochow, Louise B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; LORAZEPAM; NOVOBIOCIN; ONDANSETRON; PROCHLORPERAZINE; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG MEGADOSE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; METASTASIS; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; MODELS, BIOLOGICAL; PHENOBARBITAL; PHENYTOIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THIOTEPA;

EID: 0028801467     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Peters, W. P., Ross, M., Vredenburgh, J. J., Meisenberg, B., Marks, L. B., Winer, E., Kurtzberg, J., Bast, R. C., Jones, R., Shpall, E., Wu, K., Rosner, G., Gilbert, C., Mathias, B., Coniglio, D., Petros, W., Henderson, I. C., Norton, L., Weiss, R. B., Budman, D., and Hurd, D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol, 77: 1132–1143, 1993.
2. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antman, K., and Frei, E., III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995–1000, 1992.
3. Hill, D. L. A Review of Cyclophosphamide. Springfield, IL: Charles C Thomas, 1975.
4. Cox, P. J., Farmer, P. B., and Jarman, M. Symposium on the metabolism and mechanism of action of cyclophosphamide. Cancer Treat. Rep., 60: 299–525, 1976.
5. Friedman, O. M. Myles, A., and Colvin, M. Cyclophosphamide and related phos-phoramide mustards. Current status and future prospects. Adv. Cancer Chemother., 7: 143–204, 1979.
6. Colvin, M., and Hilton, J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep., 65(Suppl. 3):89–95, 1981.
7. Grochow, L. B., and Colvin, M. Clinical pharmacokinetics of cyclophosphamide. In: M. M. Ames, G. Powis, and J. S. Kovach, eds., Pharmacokinetics of Anticancer Agents in Humans, Vol. 6, pp. 135–154. Amsterdam: Elsevier Science Publishers B. V., 1983.
8. Grochow, L. B., and Colvin, M. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 4: 380–394, 1980.
9. Colvin, M., and Chabner, B. A. Alkylating agents. In: B. A. Chabner and J. M. Collins, eds., Cancer Chemotherapy. Philadelphia: J. B. Lippincott Company, 1990.
10. Moore, M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 20: 194–208, 1991.
11. Moore, M. J., Hardy, R. W., Thiessen, J. J., Soldin, S. J., and Erlichman, C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin. Pharmacol. Ther., 44: 622–628, 1988.
12. Motzer, R. J., Gulati, S. C., Tong, W. P., Menendez-Botet, C., Lyn, P., Mazumdar, M., Vlamis, V., Lin, S., and Bosi, G. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res., 53: 3730–3735, 1993.
13. Bagley, C. M., Jr., Botick, F. W., and DeVita, V. T., Jr. Clinical pharmacology of cyclophosphamide. Cancer Res., 33: 226–233, 1973.
14. Graham, M. I., Shaw, I. C., Souhami, R. L., Sidau, B., Harper, P. G., and McLean, A. E. M. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother. Pharmacol., 10: 192–193, 1983.
15. Sladek, N. E., Priest, J., Doeden. D., Mirocha, C. J., Pathre, S., and Krivit, W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep., 64: 1061–1066, 1980.
16. Sladek, N. E., Doeden, D., Powers, J. F., and Krivit, W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep., 68: 1247–1254, 1984.
17. Conney, A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev., 19: 317–366, 1967.
18. Sladek, N. E. Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism. Cancer Res., 32: 1848–1854, 1972.
19. D'lnacalci, M., Bolis, G., Facchinetti, T., Costantino, M., Morasca, L., Morazzoni, P., and Salmona, M. Decreased half life of cyclophosphamide in patients under continual treatment. Eur. J. Cancer, 75: 7–10, 1979.
20. Kennedy, M. J., Armstrong, D. K., Colvin, O. M., Ohly, K., Huelskamp, A. M., and Davidson, N. E. Phase I trial of novobiocin (N) in conjunction with high-dose alkylating agent chemotherapy (HDC for metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol., 12: 215A, 1993.
21. Jardine, I., Fenselau, C., Appier, M., Kan, M-N., Brundrett, R. B., and Colvin, M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res., 38: 408–415, 1978.
22. Juma, F. D., Rogers, H. J., Trounce, J. R., and Bradbrook, I. D. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother. Pharmacol., 1: 229–231, 1978.
23. Gibaldi, M., and Perrier, D. Pharmacokinetics, Ed. 2. New York: Marcel Dekker, Inc., 1982.
24. Chiou, W. L. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm., 6: 539–546, 1978.
25. Lai, A. A., and Levy, R. H. Pharmacokinetic description of drug interactions by enzyme induction: cabamazepine-clonazepam in monkeys. J. Pharm. Sci., 68: 416–421, 1979.
26. Levy, R. H., Dumain, M. S., and Cook, J. L. Time-dependent kinetics. V: Time course of drug levels during enzyme induction (one-compartment model). J. Pharmacokinet. Biopharm., 7: 557–578, 1979.
27. Levy, R. H., Lai, A. A., and Dumain, M. S. Time-dependent kinetics. IV: Pharmacokinetic theory of enzyme induction. J. Pharm. Sci., 68: 398–399,1979.
28. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53: 1–9, 1993.
29. Mouridsen, H. T., Faber, O., and Skovsted, L. The metabolism of cyclophosphamide. Cancer (Phila.), 37: 665–670, 1976.
30. Brock, N., Gross, R., Hohorst, H-J., Klein, H. O., and Schneider, B. Activation of cyclophosphamide in man and animals. Cancer (Phila.), 27: 1512–1529, 1971.
31. Lai, A. A., Levy, R. H., and Cutler, R. E. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin. Pharmacol. Ther., 24:316–323, 1978.
32. Waxman, D. J., and Azaroff, L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J., 281: 577–592, 1992.
33. Cohen, J. L., Jao, J. Y., and Jusko, W. J. Pharmacokinetics of cyclophosphamide in man. Short Communications, 677–680, 1971.
34. Henner, W. D., Shea, T. C., Furlong, E. A., Flaherty, M. D. Eder, P. J., Elias, A., Begg, C., and Antman, K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat. Rep., 71: 1043-1047, 1987.
35. Cohen, B. E., Egorin, M. J., Kohlhepp, E. A., Aisner, J., and Gutierrez, P. L. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat. Rep., 70: 859–864, 1986.
36. Clarke, L., and Waxman, D. J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res., 49: 2344–2350, 1989.
37. Ng, S., and Waxman, D. J. N,N′,N′-Triemyleiiethiophosplioraimde (Thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res., 57: 2340–2345,1991.
38. Ng, S., and Waxman, D. J. Biotransformation of N,N′,N′-triethylenethiopho8phor-amide: oxidative desulfuration of yield MAP, AT′-triewylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P450 monooxygenase. Cancer Res., 50: 464–471, 1990.
39. Veronese, M. E., Doecke, C. J., Mackenzie, P. I., McManus, M. E., Miners, J. O., Rees, D. L. P., Gasser, R., Meyer, U. A., and Birkett, D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J., 289: 533–538, 1993.
40. Jao, J. Y., Jusko, W. J., and Cohen, J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res., 32: 2761–2764, 1972.